SEARCH

SEARCH BY CITATION

References

  • 1
    Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 790816.
  • 2
    Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 2003; 17: 198695.
  • 3
    Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 2002; 190: 27986.
  • 4
    Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004; 56: 387437.
  • 5
    Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 1994; 91: 1201317.
  • 6
    Wu KK. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J. Lab. Clin. Med. 1996; 128: 2425.
  • 7
    Harrison JR, Lorenzo JA, Kawaguchi H, Raisz LG, Pilbeam C. Stimulation of prostaglandin E2 production by interleukin-1 alpha and transforming growth factor alpha in osteoblastic MC3T3-E1 cells. J. Bone Miner. Res. 1994; 9: 81723.
  • 8
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 70516.
  • 9
    Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004; 24: 234951.
  • 10
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 11838.
  • 11
    Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997; 57: 127680.
  • 12
    Liu X, Li P, Zhang ST, You H, Jia JD, Yu ZL. COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis. Esophagus 2008; 21: 914.
  • 13
    Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2003; 95: 178491.
  • 14
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 1991; 83: 3558.
  • 15
    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002; 94: 25266.
  • 16
    Hamajima N, Takezaki T, Matsuo K et al. Genotype frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac. J. Cancer Prev. 2001; 2: 5762.
  • 17
    Cox DG, Pontes C, Guino E et al.; Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br. J. Cancer 2004; 91: 33943.
  • 18
    Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br. J. Cancer 2004; 90: 17604.
  • 19
    Tan W, Wu J, Zhang X et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007; 28: 1197201.
  • 20
    Xing LL, Wang ZN, Jiang L et al. Cyclooxygenase 2 polymorphism and colorectal cancer: −765G>C variant modifies risk associated with smoking and body mass index. World J. Gastroenterol. 2008; 14: 17859.
  • 21
    Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, Fernández-Peralta AM. Effect of COX2 −765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009; 20: 14219.
  • 22
    Thompson CL, Plummer SJ, Merkulova A et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J. Gastroenterol. 2009; 15: 22404.
  • 23
    Hoff JH, Te Morsche RH, Roelofs HM, Van Der Logt EM, Nagengast FM, Peters WH. COX-2 polymorphisms −765G>C and −1195A>G and colorectal cancer risk. World J. Gastroenterol. 2009; 15: 45615.
  • 24
    Liu F, Pan K, Zhang X et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006; 13: 197584.
  • 25
    Pereira C, Sousa H, Ferreira P et al. −765G >C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J. Gastroenterol. 2006; 12: 54738.
  • 26
    Hou L, Grillo P, Zhu ZZ et al. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res. 2007; 27: 42437.
  • 27
    Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of −765G >C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. World J. Gastroenterol. 2008; 14: 1498503.
  • 28
    Sitarz R, Leguit RJ, De Leng WW et al. The COX-2 promoter polymorphism −765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod. Pathol. 2008; 21: 68590.
  • 29
    Guo Y, Zhang X, Tan W et al. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet. Genomics 2007; 17: 197205.
  • 30
    Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat. Res. 2009; 663: 529.
  • 31
    Kristinsson JO, Van Westerveld P, Te Morsche RH et al. Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J. Gastroenterol. 2009; 15: 34937.
  • 32
    Chiang SL, Chen PH, Lee CH et al. Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2-1195G>a polymorphism reveal risk of oral cancer. Cancer Res. 2008; 68: 848998.
  • 33
    Lin YC, Huang HI, Wang LH et al. Polymorphisms of COX-2 −765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008; 44: 798804.
  • 34
    Zhao D, Xu D, Zhang X et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 2009; 136: 165968.
  • 35
    Srivastava K, Srivastava A, Pandey SN, Kumar A, Mittal B. Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population. J. Gastroenterol. 2009; 44: 77480.
  • 36
    Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004; 2: 22935.
  • 37
    Panguluri RC, Long LO, Chen W et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25: 9616.
  • 38
    Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer 2007; 97: 55761.
  • 39
    Murad A, Lewis SJ, Smith GD et al. PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 2009; 12: 296300.
  • 40
    Schwartzbaum J, Ahlbom A, Malmer B et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005; 65: 645965.
  • 41
    Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006; 8: R71.
  • 42
    Cox DG, Buring J, Hankinson SE, Hunter DJ. Polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007; 9: R3.
  • 43
    Gao J, Ke Q, Ma HX et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J. Toxicol. Environ. Health A 2007; 70: 90815.
  • 44
    Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 2009; 31: 93843.
  • 45
    Lira MG, Mazzola S, Tessari G et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br. J. Dermatol. 2007; 157: 4957.
  • 46
    Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, Tjønneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat. Res. 2007; 617: 13846.
  • 47
    Hoeft B, Becker N, Deeg E, Beckmann L, Nieters A. Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes Control 2008; 19: 16373.
  • 48
    Yang H, Gu J, Lin X et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin. Cancer Res. 2008; 14: 223644.
  • 49
    Chang ET, Birmann BM, Kasperzyk JL et al. Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 97686.
  • 50
    Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, Van Doeselaar M, Van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int. J. Cancer 2006; 119: 297303.
  • 51
    Hu HM, Kuo CH, Lee CH et al. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol. 2009; 9: 37.
  • 52
    Vogel U, Christensen J, Wallin H et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat. Res. 2008; 639: 89100.
  • 53
    Ferguson HR, Wild CP, Anderson LA et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 72731.
  • 54
    Sakoda LC, Gao YT, Chen BE et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 2006; 27: 12516.
  • 55
    Campa D, Hung RJ, Mates D et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 5389.
  • 56
    Hu Z, Miao X, Ma H et al. A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005; 48: 1117.
  • 57
    Park JM, Choi JE, Chae MH et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006; 6: 70.
  • 58
    Gallicchio L, McSorley MA, Newschaffer CJ et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006; 106: 144352.
  • 59
    Langsenlehner U, Yazdani-Biuki B, Eder T et al. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin. Cancer Res. 2006; 12: 13924.
  • 60
    Shahedi K, Lindström S, Zheng SL et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer 2006; 119: 66872.
  • 61
    Danforth KN, Hayes RB, Rodriguez C et al. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 2008; 29: 56872.
  • 62
    Lee TS, Jeon YT, Kim JW et al. Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann. N. Y. Acad. Sci. 2007; 1095: 13442.
  • 63
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 1997; 127: 8206.
  • 64
    Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York: Oxford University Press, 1994.
  • 65
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 66
    Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 1998; 263: 30228.
  • 67
    Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990; 265: 1673740.
  • 68
    Dixon DA. Regulation of COX-2 expression in human cancers. Prog. Exp. Tumor. Res. 2003; 37: 5271.
  • 69
    Zhang X, Miao X, Tan W et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 56576.
  • 70
    Papafili A, Hill MR, Brull DJ et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 16316.
  • 71
    Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 65967.
  • 72
    Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3′-untranslated region. Biochem. Biophys. Res. Commun. 1998; 242: 50812.
  • 73
    Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. J. Biol. Chem. 2000; 275: 117507.
  • 74
    Jolly Janner ERC. World Cigarettes 1: the 2007 Report. ERC Statistics Intl Pic, 2007.
  • 75
    Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J. Physiol. Pharmacol. 2006; 57: 5165.
  • 76
    Stewart BW, Kleihues P. World Cancer Report. Lyon: IARC Press, 2003.
  • 77
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 2006; 12: 35462.
  • 78
    Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancers. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 97102.
  • 79
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993; 53: 13227.
  • 80
    Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Intern. Med. 1999; 159: 1616.
  • 81
    Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001; 1: 1121.